25 de febrero: 1:15 pm – 2:15 pm, hora de Buenos Aires (GMT -3)
Speakers: Jill H. Simmons, MD, Karl L. Insogna, MD, FACP

Brief:
- Overview: Phosphate Homeostasis
- Renal Phosphate Handling
- Role of Phosphatonins
- Incidence and Prevalence of XLH and TIO
- Pathogenesis and Clinical Manifestations of XLH and TIO
- Differential Diagnoses and Diagnostic Criteria
- Algorithms for the Evaluation of Children with Rickets Presenting with Hypophosphatemia
- Safety and Efficacy of Treatments for Children and Adults with XLH and TIO
- Burosumab
- Phosphate and Calcitriol
- Adjuvant Therapies
- Treatment Challenges
- Genetic Classification: PHEXMutational Analysis
- Assessing Treatment Efficacy
- Patient Follow-Up in Children and Adults with XLH and TIO
Learning Objectives
- Describe the pathophysiological mechanisms of XLH and TIO
- Evaluate the mechanisms, efficacy, and safety of agents approved for the treatment of XLH and TIO
- Develop personalized strategies for the long-term management of children and adults with XLH and TIO with ongoing disease monitoring and, when indicated, interdisciplinary clinical care
(*) Supported by an educational grant from ULTRAGENYX
26 de febrero: 1:15 pm – 2:15 pm, hora de Buenos Aires (GMT -3)

Chair: Lynette Nieman
Speakers: Lynette Nieman, John Newell-Price, Elena Valassi

Brief:
- Introduction – Lynette Nieman (Chair) (4´)
- Managing Cushing’s syndrome in the COVID era – John Newell- Price (12´)
- New evidence on metyrapone efficacy & safety: 12 weeks data from PROMPT – Lynette Nieman (12’)
- What matters to patients with Cushing’s syndrome – Elena Valassi (12’)
- Q & A (20´)
27 de febrero: 1:15 pm – 2:15 pm, hora de Buenos Aires (GMT -3)
Speakers: Bradley S. Miller, MD, PhD, Beverly Biller, MD

Brief:
- Welcome, Introductions, Sponsor Acknowledgement, Disclosures (Bradley Miller) (1´)
- Childhood-onset GHD transitioning to adult care: Diagnosis, Assessment, and Management Considerations (Bradley Miller, MD) (25´)
- Adult GHD: Diagnostic Options, Clinical Challenges, and Treatment Options of GHD with Various Causes (Beverly Biller, MD)
- Looking Ahead: Emerging Treatments for Prolonging GH Action including Long-term Management (Beverly Biller, MD) (25´)
- Audience Q&A session (9´)
(*) Supported through an educational grant from NOVO NORDISK with CME credits from EXCEL – To obtain CME credits, please click here and complete the evaluation. (link available from February 27th)